Please provide your email address to receive an email when new articles are posted on . Treatment with gefapixant, a P2X3 receptor antagonist reduced cough frequency and cough-related quality of life ...

Please provide your email address to receive an email when new articles are posted on . Gefapixant 45 mg twice daily resulted in clinically important reductions in cough frequency compared with ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165). The ...

(RTTNews) - Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential ...

Discover why coughs worsen at night and improve your sleep by trying expert tips like elevating your head at night, staying hydrated, and using cough drops.

Credit: Getty Images. Twice daily gefapixant 45 mg was associated with a clinically meaningful reduction in cough frequency in patients with chronic cough. Twice daily gefapixant 45mg was associated ...

Honey appears to be more effective in treating cough and cold symptoms than antibiotics, according to a new study. Honey is cheap and widely available, and researchers say it outperformed usual care ...

A brief course of morphine provided some relief for patients with cough related to idiopathic pulmonary fibrosis (IPF) in a small, phase II double-blind crossover trial. Two weeks of low-dose ...

Winter chills often bring bothersome coughs. It can not only leave you drained, but also interrupt sleep. Discover three ...

The investigational drug gefapixant significantly reduces cough frequency over 24 hours for patients with refractory or unexplained cough, results from two parallel phase 3 clinical trials show.

Smoking cannabis may increase the risk of respiratory disease such as chronic bronchitis, but quitting is likely to reduce the symptoms. It is unknown at this time whether cannabis use is linked to ...